

Dear Dana Harrison:

We are reviewing your Biologics License Application (BLA) dated March 24, 2014, for Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and have determined that the following information is necessary to take complete action. Please promptly submit your written response to the following items so that we may continue evaluating your BLA:

1. Please provide data to support the stability of the performance of the immunoassays used to assess responses to diphtheria, tetanus and pertussis from the time of validation to the analysis of samples in in study M5I02.
2. If you retested samples in your immunologic assays and replaced specific data points in study M5I02, please provide a summary of retesting either as part of the Clinical Study Report or separately. In this summary, we request you include a listing of the values replaced during data cleaning, reasons for sample retesting, and an assessment of the impact of the retesting and replacement of values.
3. Please provide the transfer protocols and reports for the anti-diphtheria and anti-tetanus assays described in Table 1 of Appendix 11 (Assay Techniques and Standard References) in Section 5.3.5.1, Inter Laboratory Standardisation Methods Quality Assurance.

If you have any questions, please contact the Regulatory Project Manager, Juan Lacayo, Ph.D., at (301) 796-2640.

Thanks,

juan

*Juan C. Lacayo, Ph.D.*

*LCDR, United States Public Health Service*

*Regulatory Reviewer/Project Manager*

*CMC Review Branch 1*

*Division of Vaccines and Related Product & Applications*

*Office of Vaccines Research & Review*

*Center for Biologics Evaluation & Research*

*U.S. Food and Drug Administration*

*Tel: 301-796-2640*

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.